Applications and Risks of Drug Delivery and Nanoparticles

Vidya Karhale[1], Vedant Chimote[2], Shraddha Malpani[3], Amol Sawale[4]

Abstract

One of the technologies that is being studied and used for research and development the fastest in the globe is nanotechnology.The use of nanotechnology in drug delivery systems in the form of nanoparticles (NP) is one such application where it is advancing.

Particles with sizes ranging from one to one hundred nanometers are known as nanoparticles, and due to their special physical, chemical, and physiological characteristics, they are used in a variety of applications.Particles with a size range of one to one hundred nanometers are known as nanoparticles.They can be divided into a number of different categories according to their size and shape, including dendrimers, liposomes, metallic NPs, semiconductor NPs, carbon-based NPs, polymeric NPs, and others.

Nanoparticles are used in cosmetics, cancer treatment, bone development boosters, and other medical fields. They may also be able to penetrate the blood-brain barrier and cure conditions that are site-specific.

Thanks to nanoparticles, food products can now be kept much longer on the shelf, hydrophobic medications can now be delivered more effectively within cells, and some therapies, such anticancer agents, can now work more effectively.

Keywords: **Nanotechnology, nanoparticles, drug delivery, doses, biocompatibility**.

Introduction

Delivering therapeutic medication to the intended location is a significant difficulty in the treatment of many diseases.It may be possible to get around these limitations by managing drug delivery methods. [1]

for example, by transporting drugs to the location of action using nanoparticles.1 Small, colloidal, non-biodegradable particles are known as nanoparticles.whose range is between 10 and 1000 nm The study of particles with sizes between 10-9 and 10-7 meters is known as nanotechnology.[2] By delivering the medication to a specific area or organ, nanoparticles help to reduce side effects.and lowers the therapeutic agent's dosage and frequency of administration. between 10-7 and 10-9 meters.



Fig number 1:- Image of nanoparticle. [12]

Benefits Of using nanoparticles in medication delivery systems [3]
• Nanoparticles may be stored for a long time and are non-toxic and biodegradable.
•Magnetic guiding or the addition of targeting ligands to the surface of nanoparticles can be used to accomplish site-specific targeting for reducing medication accumulation in healthy tissues.
• They manage and maintain the release of drugs while in transit andaltering medication organ distribution and subsequent clearance at the localization site to achieve enhancedtherapeutic effectiveness of drug and decreased adverse effects.
•They increase the half-life of medications, which helps to improve therapeutic efficacy. solubility of hydrophobic pharmaceuticals, reducing potential immunogenicity, and releasing chemicals gradually or in response to stimuli.[4]
• Drug transportation via cell barriers gets easier.
• Even in the tiniest vessels, fine nanoparticles are less likely to obstruct flow and to show signs of sedimentation.
• Nanomaterials can also be used primarily as carrier vehicles, making penetration simpler.[5],[6],[7]

Drug delivery with nanoparticles In the context of nanomedicine, drug transport and related pharmaceutical development should be understood as the science and technology of complex systems at the nanoscale (10–1000 nm),

Objectives
1) Greater safety and biocompatibility.[8]
2) More targeted drug delivery.
3) Decreased toxicity while preserving therapeutic effects.
4) Quicker creation of novel, safe medications

They include information on the following topics:[9],[10]
(I) drug release and integration.
(ii)stability and shelf life of formulations.
(iii) biocompatibility.
(iv) biodistribution and targeting.[11]
(v) functionality.

Disadvantages of Nanoparticles [13],[14]
Pharmaceutical scientists have utilized nanoparticles to reduce toxicity and increase drug efficacy, but until recently, they were unaware that the carrier systems could also put patients at risk.
• The process of nanotechnology is quite expensive and time-consuming.
• It raises further problems because it calls for highly skilled engineers and laborers.
•When polymers undergo biotransformation, hazardous metabolites are produced that must be administered repeatedly.[15]
•Polymeric materials degrade rather slowly.Systemic toxicity can result from nanoparticles.
•Reactions to dental implants might be extremely sensitive.
• Particle-particle collisions can occur because of nanoparticles' enormous surface area and small size.[16],[17]

Nanoparticles and drug delivery
The science and technology of nanometer scale complex systems (10–1000 nm) comprising at least two components, one of which is a pharmaceutically active ingredient, although nanoparticle formulations of the drug itself are also possible, should be viewed in the context of nanomedicine when it comes to drug delivery and related pharmaceutical development. [18] Often referred to as "smart drugs" or "theragnostics," the entire system results in a unique function associated with the treatment, prevention, or diagnosis of diseases.[19]
The principal objectives of nano-biotechnologies research in drug delivery encompass:

• More targeted and precise drug distribution;
• Lower toxicity while preserving therapeutic effects;
• Enhanced safety and biocompatibility;
• Accelerated discovery of novel, safe medications.

As fundamental preconditions for designing new materials, the following areas are crucial to the search for suitable carriers as drug delivery systems.[20],[21]
These encompass information on -
(i) drug release and integration,
(ii) stability and shelf life of formulations,
(iii) biocompatibility,
(iv) biodistribution and targeting, and
(v) functioning.
Furthermore, the potential negative consequences of remaining material following drug administration should be taken into account when using it only as a carrier. In this regard, it would be best to use biodegradable nanoparticles that have a short half-life as long as they are needed for therapeutic purposes.[22]



Fig no 2 :- nanoparticle and drug delivery [25]

Use of Nanoparticle formulations in drug delivery :-
1) Cellular and intracellular target.
2) The Brain – the ultimate target for drug delivery.
3) Targeted drug delivery system.[23]
4) Controlled release of therapeutic agents.
5) Reduce both dosage and dosage frequency.[24]

Conclusion:
There are many benefits and uses for nanoparticles, as was previously mentioned. The ability to modify the size of existing compounds/drugs into the nano range is its greatest advantage and the main driver behind its widespread use in drug delivery systems. This reduces the need to discover new drug molecules and increases the drug's activity relative to its existing moieties by increasing the surface area, which increases the compound's solubility in bodily fluids and amplifies the drug's effect. Because of their numerous uses, including as drug carriers and sites of targeted delivery that improve bioavailability, encourage patient

compliance, and minimize side effects, nanoparticles are unquestionably the way of the future for drug delivery systems. Notwithstanding their many benefits,

References

1. Bhatia.S, Natural Polymer Drug Delivery Systems. Switzerland: Springer International Publishing; 2016.
2. Wim De Jong H, Paul Borm JA .Drug delivery and nanoparticles: Applications & hazards. International Journal of Nanomedicine 2008; 3(2): 133-149. DOI - 10.2147/IJN.S596; PMID: 18686775.
3. Velavan.P, Karruppusamy.C, Venkatesan.P. Nanoparticles as Drug Delivery Systems. Journal of Pharmaceutical Sciences and Research 2015; 7(12):1118-1122.
4. Wechsler M.E, Vela Ramirez J.E, and Peppas N.A. Nanoparticles Mediated Drug Delivery for the treatment of Alzheimer's disease: crossing the blood-brain barrier. Industrial Engineering and Chemistry Research 2019; 58: 15079-15087. DOI:10.1021/acs.iecr.9b02196; PMID :32982041
5. Saba Hasan. A Review on Nanoparticles: Their Synthesis and Types. Research Journal of Recent sciences, 2015; 4:1-3.
6. Rajora A.K, Ravishankar.D, Osborn H.M.I, Greco.F. Impact of the enhanced permeability and retention (EPR) effect and cathepsins levels on the activity of polymer-drug conjugates. Polymers 2014; 6: 2186-2220.DOI:10.3390/polym6082186.
7. Lam Shu J, Wong Edgar HH, Boyer Cyrille, Qiao Greg G. Antimicrobial Polymeric Nanoparticles. Progress in Polymer Science, 2018; 76:40-64.DOI: 10.1016/j.progpolymsci.2017.07.007.
8. Lee C., MacKay.J, Fréchet, Szoka J.C. Designing dendrimers for biological applications. Nature Biotechnology, 2005; 23:1517–1526. DOI: 10.1038/ nbt1171.
9. Akbarzadeh. A., Rezaei-Sadabady.R, Davaran, Sang Woo Joo, Nosratollah Zerghami Y, Hanifehpour, Samiei.M, Kouhi.M, Koshki K.N. Liposome: classification, preparation, and applications. Nanoscale Research Letters, 2013; 8: 102. DOI: 10.1186/1556-276X-8-102.
10. Deependra Singh, Pooja Dubey, Madhulika Pradhan, Manju Rawat Singh. Ceramic nanocarriers: versatile Nano system for protein and peptide delivery. Expert Opinion on Drug Delivery, 2013; 10(2): 241-259. DOI: 10.1517/17425247.2012.745848.
11. Swartejas, J.J.T.M, Sharma P.K, Kooten, Mei T.G.V, Mahmoudi M, Busscher H.J, Rochford E.T.J. Current Developments in Antimicrobial Surface Coatings for Biomedical Applications. Current Medicinal Chemistry, 2015; 22: 2116–2129. DOI: 10.2174/0929867321666140916121355.PMID-25245508.

12. National Cancer Institute- Benefits of Nanotechnology for Cancer. [Internet] [Updated 2017 Aug 8] Available from: https://www.cancer.gov/nano/cancer- nanotechnology/benefits.
13. Farrokhzad O.C, Langer. Impact of Nanotechnology on Drug Delivery. American Chemical Society, 2009; 3(1): 16-20. DOI: 10.1021/nn900002m.
14. Walker N, Bucher J. A. 21st century paradigm for evaluating the health hazards of nanoscale materials. Toxicological Sciences, 2009; 110(2): 251-254. DOI- 10.11093/toxsci/kfp106.
15. Ballou B, Lagerholm BC, Ernst LA, et al. 2004. Non-invasive imaging of quantum dots in mice. Bioconjug Chem, 15:79–86.
16. Baran ET, Özer N, Hasirci V. 2002. In vivo half life of nanoencapsulated L-asparaginase. J Mat Sc: Mat in Med, 13:1113–21.
17. Bazile D, Prud'Homme C, Bassoullet M-T, et al. 1995. Stealth PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci, 84:493–8.
18. Benardi RJ, Lowery AR, Thompson PA, et al. 2007. Immunoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J Neurooncol, Sep 6 Epub ahead of print.
19. Borm PJ. 2002. Particle toxicology: from coal mining to nanotechnology. Inhal Toxicol, 14:311–24.

20. Borm PJ, Kreyling W. 2004. Toxicological hazards of inhaled nanoparticles – potential implications for drug delivery. J Nanosc Nanotechnol, 4:521–31.
21. Borm PJ, Muller-Schulte D. 2006. Nanoparticles in drug delivery and environmental exposure: same size, same risks? Nanomedicine,1:235–49
22. Borm PJA, Robbins D, Haubold S, et al. 2006. The potential risks of nanomaterials: a review carried out for ECETOC. Part Fiber Toxi-col, 3:11.
23. Bourges JL, Gautier SE, Delie F, et al. 2003. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci, 44:3562–9.
24. Brook RD, Franklin B, Cascio W, et al. 2004. Air pollution and vascular disease. A statement for healthcare professionals from the expert panel on population and prevention science of the American Heart Association. Circulation, 109:2655–71.
25. Buxton DB, Lee SC, Wickline SA, et al. 2003. Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation, 108:2737–42.